About this trial
Background: Pancreatic cancer (PC) is one of the most aggressive malignant neoplasms with poor outcomes. Pancreatoduodenectomy (PD) is the only curative treatment for PC. Minimally invasive surgery has been progressively developed, first with the advent of hybrid-laparoscopy and recently with the total laparoscopy surgeries, but a number of issues are currently being debated, including the superiority between total laparoscopic pancreaticoduodenectomy (TLPD)and the open pancreaticoduodenectomy (OPD). Studies comparing these two surgery techniques are merging and randomized controlled trials (RCT) are lacking but clearly required.
Methods/design: TJDBPS07 is a multicenter prospective, randomized controlled, trial comparing TLPD and OPD in pancreatic cancers. A total of 200 patients with pancreatic cancer underwent PD will be randomly allocated to the TLPD group or OPD group with an enhanced recovery after surgery (ERAS) pattern. The trial's aim is to exploring the overall survival (OS), disease free survival (DFS) and quality of life. The duration of the entire trial is seven years including prearrangement, a presumably five-year follow-up and analyses.
Discussion: Despite the fact there are several RCTs comparing minimally invasive pancreaticoduodenectomy (MIPD) and Open approach or LPD versus OPD. This trial will be the first comparing TLPD and OPD in a large multicenter setting. TJDBPS01 trial is hypothesized to assess whether TLPD has superiority over OPD in recovery and other aspects.
Eligibility criteria
Qualifiers
Age between 18 years and 75 years.
Histologically confirmed PDAC or clinically diagnosed PDAC by an MDT without histopathologic evidence.
Patients feasible to undergo both LPD and OPD according to MDT evaluations.
Patients understanding and willing to comply with this trial.
Disqualifiers
Patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.
Patients requiring left, central or total pancreatectomy or other palliative surgery.
Preoperative American Society of Anaesthesiologists (ASA) score ≥ 4.
History of other malignant disease.
Trial design
Treatments tested in this trial
- TLPD Surgery
- OPD Surgery
Treatment groups
Sponsors and collaborators
Tongji Hospital
Lead sponsor
Shandong Provincial Hospital
Collaborator
The Second Hospital of Hebei Medical University
Collaborator
The Affiliated Hospital of Xuzhou Medical University
Collaborator
Xinqiao Hospital of Chongqing
Collaborator
Hunan Provincial People's Hospital
Collaborator
The First Hospital of Jilin University
Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborator
The Third Affiliated Hospital of Soochow University
Collaborator
Guangdong Provincial Hospital of Traditional Chinese Medicine
Collaborator
Affiliated Hospital of North Sichuan Medical College
Collaborator
First Affiliated Hospital of Chongqing Medical University
Collaborator
Peking Union Medical College Hospital
Collaborator
Henan Provincial People's Hospital
Collaborator
Sir Run Run Shaw Hospital
Collaborator
Fujian Medical University Union Hospital
Collaborator
Fudan University
Collaborator